Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: A randomized, double-blind study

European Journal of Neurology

Volumn 16, Issue 1, 2009, Pages 88-94

  Millan Guerrero R O ^a,b   Isais Millan S ^c   Barreto Vizcaino S ^b   Rivera Castano L ^a   Rios Madariaga, C ^b  

^a Lomas de Circunvalación CP 28010 Colima ^*  (Mexico)

^b Hospital General de Zona IMSS   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

Author keywords

Botulinum toxin type A; H3 agonist; Histamine; Migraine; Migraine prophylaxis; Prophylaxis

Indexed keywords

BOTULINUM TOXIN A; HISTAMINE; HISTAMINE H3 RECEPTOR; PARACETAMOL; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MIGRAINE AURA; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PRIORITY JOURNAL; PROPHYLAXIS;

ADOLESCENT; ADULT; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE; HISTAMINE AGONISTS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57449089379     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02352.x     Document Type: Article

References (35)

1. Pearce JMS. Migraine. European Neurology 2005 53 : 109 110.
2. Patel NV, Bigal ME, Kolodner KB, Leotta C, Lafata JE, Lipton RB. Prevalence and impact of migraine and probable migraine in a health plan. Neurology 2004 63 : 1432 1438.
3. Bigal ME, Lipton RB. The preventive treatment of migraine. Neurologist 2006 12 : 204 213.
4. Lohman J, Van der Kuy-de Ree M. Patterns of specific antimigraine drug use - a study based on the records of 18 community pharmacies. Cephalalgia 2005 25 : 214 218.
5. Goadsby PJ, Hargreaves R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache 2008 48 : 799 804.
6. Sanchez-Del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. Current Opinion in Neurology 2006 19 : 294 298.
7. Buzzi MG, Moskowitz MA. The pathophysiology of migraine: year 2005. Journal of Headache and Pain 2005 6 : 105 111.
8. Waeber CH, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 2005 64 (Suppl. 2 S9 S15.
9. Peroutka SJ. Neurogenic inflammation and migraine: implications for therapeutics. Molecular Interventions 2005 5 : 304 311.
10. Millán-Guerrero RO, Isais CM, Antonio OA, Pacheco-Carrasco MF. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. Headache 1999 39 : 576 580.
11. Dimitriadou V, Rouleau A, Dam Trung Tuong M, et al. Functional relationship between mast cells and C-sensitive nerve fibers evidenced by histamine H3-receptor modulation in rat lung and spleen. Clinical Science 1994 87 : 151 163.
12. Arrang JM, Garbarg M, Schwartz JCH. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983 302 : 832 837.
13. West RE, Zweig A, Shih N-Y, Siegel MI, Egan RW. Identification of two H3-histamine receptor subtypes. Molecular Pharmacology 1990 38 : 610 613.
14. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache 2003 43 (Suppl. 1 9 15.
15. Straube A, Empl M, Ceballos-Baumann A, Tolle T, Stefenelli U, Pfaffenrath V. Pericranial injection of botulinum toxin type A (Dysport(R)) for tension-type headache - A multicentre, double-blind, randomized, placebo-controlled study. European Journal of Neurology 2008 15 : 205 213.
16. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004 44 : 35 42.
17. Oshinsky ML, Pozo-Rosich P, Luo J, Hyman S, Silberstein S. Botulinum toxin type A blocks sensitization of neurons in the trigeminal nucleus caudalis. Cephalalgia 2004 24 : 781.
18. Headache classification committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn. Cephalalgia 2004 24 : 1 160.
19. International Classification of Headache Disorders, Olesen J. International Classification of Headache Disorders, (ICHD-2): Current Status and Future Revisions, 2nd edn. Cephalalgia 2006 26 : 1409 1410.
20. Lipchik GL, Nicholson RA, Penzien DB. Allocation of patients to conditions in headache clinical trials: randomization, stratification and treatment matching. Headache 2005 45 : 419 428.
21. Blumenfeld AM, Binder W, Silberstein SD, Blitzer A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003 43 : 884 891.
22. HIS committee on clinical trials in migraine. Guidelines for controlled trials of drugs in migraine, 1st edn. Cephalalgia 1991 11 : 1 12.
23. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001 41 : 854 861.
24. Hulley SB, Gove S, Cummings SR. Elección de los individuos que participarán en el estudio: especificación y muestreo. In : Hulley SB, Cummings SR, eds. Diseño de la Investigación Clínica. España : Harcourt Brace, 1997 : 21 55.
25. Anand KS, Prasad A, Singh MM, Sharma S, Bala K. Botulinum toxin type A in prophylactic treatment of migraine. American Journal of Therapeutics 2006 13 : 183 187.
26. Gupta VK. Botulinum toxin - a treatment for migraine? A systematic review. Pain Medicine 2006 7 : 386 394.
27. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007 47 : 486 499.
28. Schwedt TJ, Hentz JG, Dodick DW. Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine. Cephalalgia 2007 27 : 528 534.
29. Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007 27 : 492 503.
30. Tokita S, Takahashi K, Kotani H. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine h3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. Journal of Pharmacological Sciences 2006 101 : 12 18.
31. Bigal ME, Krymchantowski V. Emerging drugs for migraine prophylaxis and treatment. Medscape General Medicine 2006 8 : 31.
32. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine 2004 350 : 1104 1110.
33. Goadsby PJ. Recent advances in the diagnosis and management of migraine. British Medical Journal 2006 332 : 25 29.
34. Loder E. Prophylaxis: headaches that never happen. Headache 2008 48 : 694 696.
35. Alstadhaug K, Bekkelund S, Salvesen R. Circannual periodicity of migraine? European Journal of Neurology 2007 14 : 983 988.